Table 1.

Characteristics of 31 patients who received atezolizumab plus bevacizumab for hepatocellular carcinoma after MTA treatment.

Cases	n = 31
Median age (interquartile range (IQR))	72 (45–88)
Sex M/F (%)	26 (84%)/5 (16%)
Etiology (HBV/HCV/NASH/ASH)	4 (13%)/11 (35%)/9 (29%)/7 (23%)
mALBI grade (1/2a/2b/3) (%)	7 (23%)/8 (26%)/15 (48%)/1 (3%)
Child–Pugh (5/6/7/8) (score)	17 (55%)/10 (32%)/3 (10%)/1 (3%)
BCLC B/C (%)	15 (48%)/16 (52%)
Up to 7 in/out (%)	5 (33%)/10 (67%)
Treatment line (%) (2/3/4/5/6)	17 (55%)/7 (22%)/5 (17%)/1 (3%)/1 (3%)
Time from initial TKI (m) (IQR)	18 (13–22)
Alpha-fetoprotein ≥ 400ng/mL (%)	14 (47)
Presence of macrovascular invasion (%)	4 (13)
Presence of extrahepatic spread (%)	12 (39)
Pretreatment n (ORR/DCR of pretreatment)	Len: 20 (30%/80%) Sor: 2(0%/50%) Reg: 3 (0%/33%) Ram: 6 (0%/16%)
Reasons for switching from previous treatment (AE/PD)(%)	7 (23%)/24 (77%)

Data are expressed as median (first-third quartiles) or number (%).

Baseline data was determined at the time of atezolizumab plus bevacizumab initiation.

AE = adverse event, ASH = alcoholic steatohepatitis, BCLC = Barcelona Clinic Liver Cancer, DCR = disease control rate, HBV = hepatitis B virus, HCV = hepatitis C virus, NASH = nonalcoholic steatohepatitis, PD = progressive disease, ORR = overall response rate, TKI = tyrosine kinase inhibitor.